PMID- 36722454 OWN - NLM STAT- MEDLINE DCOM- 20230314 LR - 20230918 IS - 2398-9238 (Electronic) IS - 2398-9238 (Linking) VI - 6 IP - 2 DP - 2023 Mar TI - Two-year trends from the LANDMARC study: A 3-year, pan-India, prospective, longitudinal study on the management and real-world outcome in patients with type 2 diabetes mellitus. PG - e404 LID - 10.1002/edm2.404 [doi] LID - e404 AB - INTRODUCTION: There are limited data on the real-world management of diabetes in the Indian population. In this 2-year analysis of the LANDMARC study, the management of type 2 diabetes mellitus (T2DM) and related complications were assessed. METHOD: This multicenter, observational, prospective study included adults aged >/=25 to /=2 years at enrollment) and controlled/uncontrolled on >/=2 anti-diabetic agents. This interim analysis at 2 years reports the status of glycaemic control, diabetic complications, cardiovascular (CV) risks and therapy, pan-India including metropolitan and non-metropolitan cities. RESULTS: Of the 6234 evaluable patients, 5318 patients completed 2 years in the study. Microvascular complications were observed in 17.6% of patients (1096/6234); macrovascular complications were observed in 3.1% of patients (195/6234). Higher number of microvascular complications were noted in patients from non-metropolitan than in metropolitan cities (p < .0001). In 2 years, an improvement of 0.6% from baseline (8.1%) in mean glycated haemoglobin (HbA1c) was noted; 20.8% of patients met optimum glycaemic control (HbA1c < 7%). Hypertension (2679/3438, 77.9%) and dyslipidaemia (1776/3438, 51.7%) were the predominant CV risk factors in 2 years. The number of patients taking oral anti-diabetic drugs in combination with insulin increased in 2 years (baseline: 1498/6234 [24.0%] vs. 2 years: 1917/5763 [33.3%]). While biguanides and sulfonylureas were the most commonly prescribed, there was an evident increase in the use of dipeptidyl peptidase-IV inhibitors (baseline: 3049/6234, 48.9% vs. 2 years: 3526/5763, 61.2%). CONCLUSION: This longitudinal study represents the control of T2DM, its management and development of complications in Indian population. CLINICAL TRIAL REGISTRATION NUMBER: CTRI/2017/05/008452. CI - (c) 2023 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. FAU - Das, Ashok K AU - Das AK AUID- ORCID: 0000-0003-1770-1885 AD - Pondicherry Institute of Medical Sciences, Puducherry, India. FAU - Kalra, Sanjay AU - Kalra S AUID- ORCID: 0000-0003-1308-121X AD - Bharti Hospital, Karnal, India. FAU - Joshi, Shashank AU - Joshi S AD - Lilavati Hospital, Mumbai, India. FAU - Mithal, Ambrish AU - Mithal A AD - Medanta- The Medicity, Gurgaon, India. FAU - Kumar K M, Prasanna AU - Kumar K M P AD - Centre for Diabetes and Endocrine Care, Bengaluru, India. FAU - Unnikrishnan, Ambika G AU - Unnikrishnan AG AD - Chellaram Diabetes Institute, Pune, India. FAU - Thacker, Hemant AU - Thacker H AD - Bhatia Hospital, Mumbai, India. FAU - Sethi, Bipin AU - Sethi B AD - Care Hospital, Hyderabad, India. FAU - Chowdhury, Subhankar AU - Chowdhury S AD - IPGME and R and SSKM Hospital, Kolkata, India. FAU - Sugumaran, Amarnath AU - Sugumaran A AUID- ORCID: 0000-0001-9207-5605 AD - Sanofi, Mumbai, India. FAU - Mohanasundaram, Senthilnathan AU - Mohanasundaram S AUID- ORCID: 0000-0001-8615-6695 AD - Sanofi, Mumbai, India. FAU - Menon, Shalini K AU - Menon SK AD - Sanofi, Mumbai, India. FAU - Salvi, Vaibhav AU - Salvi V AD - Sanofi, Mumbai, India. FAU - Chodankar, Deepa AU - Chodankar D AD - Sanofi, Mumbai, India. FAU - Thaker, Saket AU - Thaker S AD - Sanofi, Mumbai, India. FAU - Trivedi, Chirag AU - Trivedi C AD - Sanofi, Mumbai, India. FAU - Wangnoo, Subhash K AU - Wangnoo SK AD - Apollo Hospital Education and Research Foundation, New Delhi, India. FAU - Zargar, Abdul H AU - Zargar AH AD - Center for Diabetes and Endocrine Care, Srinagar, India. FAU - Rais, Nadeem AU - Rais N AD - Chowpatti Medical Centre, Mumbai, India. LA - eng SI - CTRI/CTRI/2017/05/008452 PT - Journal Article PT - Multicenter Study PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20230201 PL - England TA - Endocrinol Diabetes Metab JT - Endocrinology, diabetes & metabolism JID - 101732442 RN - 0 (Glycated Hemoglobin) RN - 0 (Hypoglycemic Agents) SB - IM MH - Adult MH - Humans MH - *Diabetes Mellitus, Type 2/drug therapy MH - Prospective Studies MH - Glycated Hemoglobin MH - Longitudinal Studies MH - Hypoglycemic Agents/therapeutic use PMC - PMC10000633 OTO - NOTNLM OT - cardiovascular diseases OT - diabetes complications OT - diabetic nephropathies OT - glycaemic control COIS- AKD, AM, AGU and NR received honoraria from Sanofi and other pharmaceutical companies. KMPK is on the advisory board of Sanofi and received an honorarium for his talks. SJ received speaker/advisory/research grants from Abbott, AstraZeneca, Biocon, Boehringer Ingelheim (BI), Eli Lilly, Franco Indian, Glenmark, Lupin, Marico, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Serdia, Twinhealth and Zydus. SK received honoraria/speaker fees from Eli Lilly, Novo Nordisk and Sanofi. HT received honoraria from MSD, Novartis, Sanofi and other companies for advice and lectures. BS received an honorarium from Aventis, Novo Nordisk, Eli Lilly, BI and MSD. SC received honoraria/grants from Biocon, BI, Intas, Novartis, Sanofi and Serdia. SKW has nothing to declare. AHZ received honoraria from Novo Nordisk, Eli Lilly, Johnson & Johnson, AstraZeneca, BI and Sanofi. AS, SM, SKM, DC, VS, ST and CT are employees of Sanofi and may hold stock options. EDAT- 2023/02/02 06:00 MHDA- 2023/03/15 06:00 PMCR- 2023/02/01 CRDT- 2023/02/01 06:43 PHST- 2022/10/31 00:00 [received] PHST- 2023/01/02 00:00 [accepted] PHST- 2023/02/02 06:00 [pubmed] PHST- 2023/03/15 06:00 [medline] PHST- 2023/02/01 06:43 [entrez] PHST- 2023/02/01 00:00 [pmc-release] AID - EDM2404 [pii] AID - 10.1002/edm2.404 [doi] PST - ppublish SO - Endocrinol Diabetes Metab. 2023 Mar;6(2):e404. doi: 10.1002/edm2.404. Epub 2023 Feb 1.